Francois Lemare
Overview
Explore the profile of Francois Lemare including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Annereau M, Hinterlang M, Bienayme H, Vassal G, Pinon A, Schmitt M, et al.
Pharmaceuticals (Basel)
. 2022 May;
15(5).
PMID: 35631381
The development of oral pediatric forms by pharmaceutical companies is still insufficient. In fact, many drugs used in paediatric oncology, such as temozolomide, are not labeled and adapted for paediatric...
2.
Mir O, Ferrua M, Fourcade A, Mathivon D, Duflot-Boukobza A, Dumont S, et al.
Nat Med
. 2022 Apr;
28(6):1224-1231.
PMID: 35469070
Strategies that individualize the care of cancer patients receiving oral anticancer agents offer opportunities to improve treatment adherence and patient care. However, the impact of digital remote monitoring systems in...
3.
Desmaris R, Bermudez E, Annereau M, Lemare F, Slimano F
J Oncol Pharm Pract
. 2020 Oct;
27(7):1699-1703.
PMID: 33108989
Objective: The development of oncology day-hospital activities contributes to increase quality of life of patients and consequently have changed their perception about waiting. The extemporaneous preparation of antineoplastic has become...
4.
Federici L, Capelle L, Annereau M, Bielle F, Willekens C, Dehais C, et al.
Neuro Oncol
. 2020 Mar;
22(8):1226-1228.
PMID: 32215616
No abstract available.
5.
Michot J, Annereau M, Danu A, Legoupil C, Bertin L, Chahine C, et al.
Eur J Haematol
. 2019 Dec;
104(4):281-290.
PMID: 31838764
Background: High-dose cyclophosphamide to treat solid refractory tumors demonstrated meaningful activity, while data to treat lymphoma remain scarce. This study aims to assess high-dose cyclophosphamide to treat relapsed or refractory...
6.
Palomar Coloma V, Bravo P, Lezghed N, Mayache-Badis L, Herrera Gomez R, Iacob M, et al.
ESMO Open
. 2018 Aug;
3(5):e000346.
PMID: 30094066
Background: Cetuximab is crucial in the management of squamous cell carcinoma of the head and neck of patients. Grade 3-4 cetuximab-induced infusion reactions (CI-IRs) occur in 2% of patients with...
7.
Slimano F, Netzer F, Borget I, Lemare F, Besse B
Int J Clin Pharm
. 2018 May;
40(5):1265-1271.
PMID: 29744791
Background The role of olanzapine in the treatment of chemotherapy-induced nausea and vomiting (CINV) in addition to the antiemetic therapeutic combination with aprepitant, setrons, and corticosteroids has not been well...
8.
Hebert G, Minvielle E, Palma M, Lemare F
Bull Cancer
. 2018 Mar;
105(3):245-255.
PMID: 29486920
Purposes: Analyze the relationship and expectations of cancer patients towards the community pharmacist in a pharmaceutical care coordination project. Methods: In November 2014, a questionnaire was distributed to ambulatory patients...
9.
Hebert G, Netzer F, Kouakou S, Lemare F, Minvielle E
Int J Clin Pharm
. 2018 Feb;
40(2):376-385.
PMID: 29446003
Background Adverse drug events (ADEs) occur frequently in oncology and justify continuous assessment and monitoring. There are several methods for detecting them, but the trigger tool method seems the most...
10.
Maritaz C, Lemare F, Laplanche A, Demirdjian S, Valteau-Couanet D, Dufour C
BMC Cancer
. 2018 Feb;
18(1):177.
PMID: 29433564
Background: Serious neurological adverse events (NAE) have occurred during treatment with high-dose thiotepa regimens of children with high-risk solid tumours. The objective was to assess the incidence of NAE related...